Publication & Citation Trends
Publications
0 total
Abstract CT255: Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors
Cited by 0
Semantic Scholar
Definition of a novel breast tumor-specific classifier based on secretome analysis OA
Cited by 3
Semantic Scholar
The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner OA
Cited by 42
Semantic Scholar
Abstract LB220: The anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1-dependent manner
Cited by 2
Semantic Scholar
Abstract LB135: Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/S095012, a PD-L1/4-1BB bispecific compound for tumor localized activation of the immune system
Cited by 1
Semantic Scholar
Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm OA
Cited by 61
Semantic Scholar
A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer OA
Cited by 28
Semantic Scholar
Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific
Cited by 188
Semantic Scholar
Research Topics
Monoclonal and Polyclonal Antibodies Research
(38)
CAR-T cell therapy research
(38)
Radiopharmaceutical Chemistry and Applications
(34)
Immunotherapy and Immune Responses
(5)
Cancer Immunotherapy and Biomarkers
(3)
Affiliations
Johns Hopkins University
Inserm
University of Toronto
Université Paris Sciences et Lettres
Canada Research Chairs